Edition:
United Kingdom

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

20.70CHF
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
CHF20.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
331,473
52-wk High
CHF22.90
52-wk Low
CHF10.00

Summary

Name Age Since Current Position

Jean-Pierre Garnier

69 Non-Executive Chairman of the Board

Jean-Paul Clozel

62 Chief Executive Officer, Member of the Board

Andre Muller

53 Chief Financial Officer, Executive Vice President, Member of the Executive Board

Martine Clozel

61 Executive Vice President, Chief Scientific Officer, Member of the Executive Board

Guy Braunstein

60 Executive Vice President, head of global clinical development, Member of the Executive Board

Robert Bertolini

55 Non-Executive Director

John Greisch

62 Non-Executive Director

David Stout

63 Non-Executive Director

Herna Verhagen

51 Non-Executive Director

Biographies

Name Description

Jean-Pierre Garnier

Dr. Jean-Pierre (JP) Garnier, Ph.D. is Non-Executive Chairman of the Board of Idorsia Ltd. He has been chairman of Actelion’s board of directors since September 2011 and member of its board since May 2011. Dr. Garnier also serves on the boards of directors of United Technologies Corporation, Radius Health, Inc. and Alzheon, Inc., and acts as operating partner at Advent International Corporation. Dr. Garnier was CEO of Laboratoires Pierre Fabre from 2008 to 2010. From 2001 to 2008 he was the first CEO of GlaxoSmithKline. Dr. Garnier joined SmithKline Beecham in 1990 as president of its pharmaceutical business in North America. He was appointed as chief operating officer in 1995 and as CEO in April 2000. Dr. Garnier also previously held various management positions at Schering-Plough. Dr. Garnier is an officer of the Légion d’Honneur and a Knight Commander of the Order of the British Empire.

Jean-Paul Clozel

Dr. Jean-Paul Clozel is Chief Executive Officer, Member of the Board at Idorsia Ltd. He founded Actelion in 1997 together with his wife, Martine Clozel, Walter Fischli, Thomas Widmann and André J. Mueller. First mainly focusing on research and development, he became CEO and executive member of Actelion’s board of directors to take Actelion public in April 2000. Previously, Dr. Clozel spent several years as a practicing cardiologist. He then moved to applied research, spending 12 years at F. Hoffmann-La Roche Ltd.

Andre Muller

Mr. Andre C. Muller is Chief Financial Officer, Executive Vice President, Member of the Executive Board at Idorsia Ltd. He joined Idorsia from Actelion, where he has worked since 2013. Previously, Mr. Muller worked at Pierre Fabre SA, where he held various positions from 1994 until 2011, most recently as chief financial officer from 2002. Mr. Muller holds an MBA from EM LYON Business School in Lyon, France.

Martine Clozel

Ms. Martine Clozel is Executive Vice President, Chief Scientific Officer, Member of the Executive Board at Idorsia Ltd. She joined Idorsia from Actelion, which she co-founded in 1997. Previously, Dr. Clozel spent 11 years at F. Hoffmann-La Roche Ltd, where she initiated the research project on endothelin and endothelin receptor antagonists. Dr. Clozel is a pediatrician specializing in neonatal intensive care, has an MD degree from Nancy University, France, and received further training in physiology and pharmacology from McGill University, Montreal, Canada and the University of California, San Francisco, U.S.

Guy Braunstein

Dr. Guy Braunstein is Executive Vice President, head of global clinical development, Member of the Executive Board at Idorsia Ltd. He joined Idorsia from Actelion, where he has worked since 2009. Prior to his position at Actelion, Dr. Braunstein was chief medical officer at Merck Serono, having served for four years before that as chief medical officer (international) at Serono. Previously, Dr. Braunstein held various executive positions at Astra, Glaxo-Wellcome, GSK, Fisons, Rhône-Poulenc Rorer and Chiron. Dr. Braunstein is an MD, pulmonologist and holds a PhD in life science from Paris University, France.

Robert Bertolini

Mr. Robert J. (Bob) Bertolini is Non-Executive Director at Idorsia Ltd. He joined the board of Actelion in 2011. He is a member of the Board of Bristol Myers Squibb, Charles River Laboratories International, Inc. and Physicians World, LLC (unlisted), and is a former member of the Board of Genzyme Corporation. Mr. Bertolini formerly served as Executive Vice President and Chief Financial Officer at Schering Plough Corporation, was formerly President and Chief Financial Officer of Bausch & Lomb Inc., and spent 20 years at PricewaterhouseCoopers. Mr. Bertolini is a Certified Public Accountant.

John Greisch

Mr. John J. Greisch is Non-Executive Director of Idorsia Ltd. He joined the board of Actelion in 2013. He is also currently President and Chief Executive Officer of Hill-Rom Holdings, Inc. Mr. Greisch also serves on the Board of Ann and Robert Lurie Children’s Hospital in Chicago and is a member of the Board of AdvaMed, Advanced Medical Technology Association, Washington D.C. Before joining Hill-Rom, Mr. Greisch spent seven years at Baxter International, Inc. in various executive positions in corporate finance, operations and general management. From 2004–2006, he served as Chief Financial Officer and from 2006–2009 as President International Operations.

David Stout

Mr. David M. Stout is Non-Executive Director at Idorsia Ltd. He joined the board of Actelion in 2015. He also serves on the Boards of Airgas, Inc., Jabil, Inc. and NanoBio Corporation and is a former member of the Board of Shire, plc. Mr. Stout was President, Pharmaceutical Operations at GlaxoSmithKline, from 2003 to 2008. Prior to this Mr. Stout was President of GlaxoSmithKline’s US pharmaceuticals business and Director of US Sales and Marketing at SmithKline Beecham. Before joining SmithKline Beecham, Mr. Stout held various executive and sales and positions with Schering-Plough. Mr. Stout holds a BA in Biology.

Herna Verhagen

Ms. Herna Verhagen is Non-Executive Director at Idorsia Ltd. She become a member of Actelion’s board in 2015. Since 2012, Ms. Verhagen is Chief Executive Officer of PostNL N.V.. Prior to this Ms. Verhagen served as member of the Board of Management and held various executive positions within the TNT N.V. Group. Ms. Verhagen also serves in the Supervisory Board of Rexel S.A. and is a member of the Executive Committee and General Board of the Confederation of Netherlands Industry and Employers (VNO-NCW). Ms. Verhagen holds a MSc in Human Resource Studies and an LLM in Business Law.